SecurityVRTX / Vertex Pharmaceuticals Inc.
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Shares15,509
Value $ 2,636,000

Bridgewater Associates, LP ownership in VRTX / Vertex Pharmaceuticals Inc.

August 13, 2018 - Bridgewater Associates, LP has filed a 13F-HR form disclosing ownership of 15,509 shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) with total holdings valued at $2,636,000 USD as of June 30, 2018. Bridgewater Associates, LP had filed a previous 13F-HR on November 13, 2017 disclosing 0 shares of Vertex Pharmaceuticals Inc. at a value of $0 USD.

Other investors with positions similar to Bridgewater Associates, LP include Two Sigma Securities, Llc, RMB Capital Management, LLC, Nuveen Asset Management, LLC, Advisors Asset Management, Inc., Bayesian Capital Management, LP, and Brinker Capital Inc.

VERTEX PHARMACEUTICALS INC / MA has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Bridgewater Associates, LP's top industries are "Printing, Publishing, And Allied Industries" (sic 27), "Rubber And Miscellaneous Plastics Products" (sic 30), and "Stone, Clay, Glass, And Concrete Products" (sic 32).

Bridgewater Associates, LP ownership in VRTX / Vertex Pharmaceuticals Inc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR VERTEX PHARMACEUTICALS COM 92532F100 15,509 2,636 2,636 0
2017-09-30 13F-HR VERTEX PHARMACEUTICALS COM 92532F100 0 -100.00 0 -100.00 -2,406 0
2017-06-30 13F-HR VERTEX PHARMACEUTICALS COM 92532F100 18,673 2,406

Related SEC Filings

VRTX / Vertex Pharmaceuticals Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) VERTEX PHARMACEUTICALS INC / MA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92532F100 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

VRTX / Vertex Pharmaceuticals Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) VERTEX PHARMACEUTICALS INC / MA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92532F100 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

VRTX / Vertex Pharmaceuticals Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 VERTEX PHARMACEUTICALS INC COMMON STOCK Cusip #92532F100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92532F100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,925,680 Item 6: 0 Item 7: 16,923,002 Item 8: 0 Item 9: 16,923,002 Item 11: 6.

VRTX / Vertex Pharmaceuticals Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 VERTEX PHARMACEUTICALS INC COMMON STOCK Cusip #92532F100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92532F100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,925,680 Item 6: 0 Item 7: 16,923,002 Item 8: 0 Item 9: 16,923,002 Item 11: 6.

VRTX / Vertex Pharmaceuticals Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
vertexpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Vertex Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  92532F100     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is

Related News Stories

Long-Term Outlook For Vertex Pharmaceuticals: October 13, 2018

2018-10-14 seekingalpha
Vertex Pharmaceuticals has been a rising star in the biotech field, with excellent price action for well over a year now (excluding the latest dip).

3 High-Reward Stocks From 3 Emerging Trends

2018-10-13 investorplace
Think of the extraordinary change someone born in 1900 would have seen over a long life. They would see horses in city streets as a child and grow up to see those same streets full of cars. They would see the invention of the radio, the airplane, the fax machine and air conditioning. And the list of big changes goes on. (8-4)

The October Pause That Refreshes

2018-10-11 seekingalpha
The much-awaited correction is finally here; the question is who will step up to the plate and will actually use it as a long-term buying opportunity. (36-0)

CRISPR Wins FDA Approval for Human Trials

2018-10-11 247wallst
CRISPR Therapeutics A.G. (NASDAQ: CRSP) shares made a handy gain on Thursday after the company announced a key U.S. Food and Drug Administration (FDA) decision concerning its collaboration with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).

J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings

2018-10-11 zacks
We expect Johnson & Johnson (JNJ - Free Report) , a healthcare bellwether, to beat expectations when it reports third-quarter 2018 results on Oct 16, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 1.94%. (13-0)



CUSIP: 92532F100